GRAF ACQUISITION CORP. IV
1790 Hughes Landing Blvd., Suite 400
The Woodlands, Texas 77380
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
TO BE HELD ON MAY 22, 2023
TO THE STOCKHOLDERS OF GRAF ACQUISITION CORP. IV:
You are cordially invited to attend the special meeting (“Special Meeting”) of stockholders of Graf Acquisition Corp. IV (“we”, “us”, “our” or the “Company”), to be held at 11:00 a.m. Eastern Time on May 22, 2023.
The Special Meeting will be a virtual meeting of stockholders, which will be conducted via live webcast. You will be able to attend the Special Meeting online, vote and submit your questions during the Special Meeting by visiting https://www.cstproxy.com/grafiv/2023.
Even if you plan to attend the Special Meeting online, please promptly submit your proxy vote by completing, signing, dating and returning the enclosed proxy card in the accompanying pre-addressed postage paid envelope, so that your shares will be represented at the Special Meeting. Voting instructions are included in the proxy materials provided for the Special Meeting. Again, even if you plan to attend the Special Meeting online, it is strongly recommended that you complete and return your proxy card before the Special Meeting date to ensure that your shares will be represented at the Special Meeting.
The accompanying proxy statement (the “Proxy Statement”), is dated May 3, 2023, and is first being mailed to stockholders of the Company on or about May 5, 2023. The sole purpose of the Special Meeting is to consider and vote upon the following two proposals:
1.
Extension Amendment Proposal. A proposal to amend the Company’s amended and restated certificate of incorporation (the “Charter”), in the form set forth in Annex A to the accompanying Proxy Statement, to (i) extend the date by which the Company must consummate the Business Combination (as defined below) from May 25, 2023 to September 29, 2023 (the “Extended Date”), and (ii) permit the Company’s board of directors (the “Board”), in its sole discretion, to elect to wind up the Company’s operations on an earlier date than the Extended Date as determined by the Board and included in a public announcement (the “Extension”, and the proposal, the “Extension Amendment Proposal”); and
2.
Adjournment Proposal. A proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal, or to provide additional time to effectuate the Extension (the “Adjournment Proposal”).
Each of the Extension Amendment Proposal and the Adjournment Proposal is more fully described in the accompanying Proxy Statement. Approval of the Extension Amendment Proposal is a condition to the implementation of the Extension. However, the Extension Amendment Proposal and Adjournment Proposal are not conditioned on the approval of any other proposal.
Our prospectus for our initial public offering (“IPO”) and our Charter currently provide that we have until May 25, 2023 (the “Current Outside Date”) to complete an initial business combination. On April 14, 2023, we entered into an Agreement and Plan of Merger for a business combination with NKGen Biotech, Inc. (“Target”), pursuant to which Target will become a wholly-owned subsidiary of the Company and the Company will change its name to “NKGen Biotech, Inc.” (the “Merger Agreement” and the transactions contemplated thereby, the “Business Combination”). Target is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer cell therapeutics. Target is based in Santa Ana, CA, and has been funded since its inception in 2017 primarily by its majority stockholder, NKMAX Co., Ltd. (“NKMAX”), a public company based in the Republic of Korea. The purpose of the Extension Amendment Proposal is to allow us additional time to complete the Business Combination with Target. The Business Combination has been approved by the board of directors